Migraine medication Imitrex recalled by Health Canada

GlaxoSmithKline has issued a voluntary recall for two lots of migraine medication Imitrex.

Voluntary recall due to possibility of needles protruding from protective shields

GlaxoSmithKline has issued a voluntary recall for two lots of migraine medication Imitrex. 

The recall of Lots C637078 and C632842 was made in consultation with Health Canada.

The medication comes in pre-filled syringes with a sterile needle for injection.

Health Canada says needles in the affected lots may be protruding through their protective plastic shields and are no longer sterile.

There is a potential risk of infection to consumers when using the product because of the protrusion.

For more details on the Imitrex injection recall, visit the Health Canada website.

Comments

To encourage thoughtful and respectful conversations, first and last names will appear with each submission to CBC/Radio-Canada's online communities (except in children and youth-oriented communities). Pseudonyms will no longer be permitted.

By submitting a comment, you accept that CBC has the right to reproduce and publish that comment in whole or in part, in any manner CBC chooses. Please note that CBC does not endorse the opinions expressed in comments. Comments on this story are moderated according to our Submission Guidelines. Comments are welcome while open. We reserve the right to close comments at any time.